Unexpectedly long persistence of anti-SARS-CoV-2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients

Transpl Infect Dis. 2023 Dec;25(6):e14164. doi: 10.1111/tid.14164. Epub 2023 Oct 4.

Authors

Quentin Perrier¹, Julien Lupo², Olivier Epaulard³

Affiliations

¹ Univ. Grenoble Alpes, INSERM, Pharmacy Department, Grenoble Alpes University Hospital, LBFA, Grenoble, France.
² Univ. Grenoble Alpes, CNRS, Virology Laboratory, Grenoble Alpes University Hospital, IBS, CEA, Grenoble, France.
³ Univ. Grenoble Alpes, Groupe de Recherche en Infectiologie Clinique, CIC1406-INSERM, Infectious Diseases Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

PMID: 37793061
DOI: 10.1111/tid.14164

No abstract available

Keywords: SARS-CoV-2; cilgavimab; immunocompromised; monoclonal antiboy; serology; tixagevimab.

MeSH terms

Antibodies, Monoclonal / therapeutic use
COVID-19*
Humans
Immunocompromised Host

Substances

tixagevimab
cilgavimab
Antibodies, Monoclonal